Read in Spanish
The non-psychoactive cannabinoid cannabidiol (CBD) is effective for the treatment of patients with seizures related to the Lennox-Gastaut syndrome. This is the result of a study funded by GW Pharmaceuticals on a drug tested in 24 clinics in the Netherlands, the United States and Poland.
The study led by the researchers of the Pediatric Epilepsy Program at the Massachusetts General Hospital in Boston was conducted during 2015 and has just been published in the prestigious journal The Lancet.
The researchers administered placebo to 171 random participants.
On a daily basis, patients received 20 mg / kg of oral CBD daily for 14 weeks without interrupting their usual medication. The age understood was between 2 and 55 years.
“The average percentage reduction in the frequency of monthly seizures from the baseline was 43.9% in the CBD group and 21.8% in the placebo group. Adverse events occurred in 86% of patients in the CBD group and in 69% of the placebo group; most were mild or moderate.” study notes.
Among the adverse effects recorded are diarrhea, vomiting, drowsiness and low appetite. The authors conclude that in general the placebo or the CBD-based medication administered is generally well tolerated. Long-term efficacy is being reviewed in an extension of this clinical trial.
This is not the first time that a clinical study has proven the efficacy of CBD. Today, a wide range of products are being marketed around the world.
Consult the study: https://bit.ly/2HsnDPq
Follow us on Instagram